前列腺癌激素治疗男性心血管事件:FAERS数据库分析
基于FAERS药物警戒数据库的回顾性分析,检索2000年1月至2020年4月前列腺癌激素治疗男性的心血管不良事件报告。单药治疗中心血管事件6231份(12.6%),联合治疗1793份(26.1%)。与GnRH激动剂相比,GnRH拮抗剂单药及联合治疗的心血管事件报告更少。
要点
- 动脉血管事件是激素治疗中最常报告的心血管不良事件。
- GnRH拮抗剂较GnRH激动剂心血管事件报告更少(单药ROR=0.70)。
- 二代雄激素受体拮抗剂和阿比特龙与更多需住院的高血压报告相关。
核心结论
- 动脉血管事件是前列腺癌激素治疗男性中最常报告的心血管不良事件。
- GnRH拮抗剂较GnRH激动剂与更少的心血管事件和动脉血管事件报告相关。
研究设计与样本
- 回顾性药物警戒数据库分析,查询美国FDA不良事件报告系统(FAERS)。
- 纳入2000年1月至2020年4月前列腺癌接受激素治疗的男性心血管不良事件报告。
主要发现
- 单药治疗心血管事件报告6231份(12.6%),联合治疗1793份(26.1%)。
- 动脉血管事件最常见,其次为心律失常、心力衰竭和静脉血栓栓塞。
- GnRH拮抗剂单药心血管事件报告少于GnRH激动剂(校正ROR=0.70,95%CI 0.59-0.84,p<0.001)。
- GnRH拮抗剂联合治疗心血管事件报告少于GnRH激动剂(ROR=0.47,95%CI 0.34-0.67,p<0.0001),由动脉血管事件减少驱动。
- 二代雄激素受体拮抗剂和阿比特龙分别与更多需住院的高血压报告相关(ROR=1.21,95%CI 1.03-1.41,p=0.02;ROR=1.19,95%CI 1.01-1.40,p=0.03)。
临床怎么用
- 选择激素治疗药物时,可考虑GnRH拮抗剂较GnRH激动剂心血管事件报告更少的信号。
- 使用二代雄激素受体拮抗剂或阿比特龙时,关注高血压和心力衰竭风险,尤其与GnRH拮抗剂联用时。
局限性
- 回顾性药物警戒数据库分析,报告存在自发上报偏倚,不能确定因果关系。
- 需进一步研究确定减少前列腺癌激素治疗男性心血管疾病的最佳策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The comparative cardiovascular risk profiles of available hormone therapies for the treatment of prostate cancer is not known. MATERIALS AND METHODS: We queried the U.S. Food and Drug Administration Adverse Event Reporting System, a retrospective, pharmacovigilance database, for cardiovascular adverse event reports in men with prostate cancer receiving gonadotropin releasing hormone (GnRH) agonists, GnRH antagonists, androgen receptor antagonists, and/or androgen synthesis inhibitors from January 2000 to April 2020. RESULTS: Cardiovascular adverse events accounted for 6,231 reports (12.6%) on hormone monotherapy and 1,793 reports (26.1%) on combination therapy. Arterial vascular events were reported most commonly, followed by arrhythmias, heart failure, and venous thromboembolism. Compared to GnRH agonists, GnRH antagonists were associated with fewer cardiovascular adverse event reports as monotherapy (adjusted reporting odds ratio [ROR]=0.70 [95% CI 0.59-0.84], p <0.001) and as combination therapy (ROR=0.47 [0.34-0.67], p <0.0001), driven by reductions in arterial vascular events. Second generation androgen receptor antagonists and abiraterone were associated with more reports of hypertension requiring hospitalization (ROR=1.21 [1.03-1.41], p=0.02 and ROR=1.19 [1.01-1.40], p=0.03, respectively), and more heart failure events when used in combination with GnRH antagonists (ROR=2.79 [1.30-6.01], p=0.009 and ROR=2.57 [1.12-5.86], p=0.03). CONCLUSIONS: In this retrospective analysis of a pharmacovigilance database, arterial vascular events were the most commonly reported cardiovascular adverse events in men on hormone therapy for prostate cancer. GnRH antagonists were associated with fewer reports of overall cardiovascular events and arterial vascular events than GnRH agonists. Additional study is needed to identify optimal strategies to reduce cardiovascular morbidity among men with prostate cancer receiving hormone therapy.
引用
- Zhang KW, Reimers MA, Calaway AC, et al. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). J Urol. 2021. PMID: 33872049. doi:10.1097/JU.0000000000001785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。